ArticleBiomarker research2024
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.
Article in Biomarker research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.Journal for immunotherapy of cancer · 2025Trial
- Microbiome-Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Review
- Regulation of PD-1PD-L1 Immune Checkpoints by Gut Microbiota Metabolites and Their Clinical Translational Research: A Review.Immunity, inflammation and disease · 2026Review
- Dietary yacon concentrate reshapes microbial-metabolite crosstalk to inhibit colorectal cancer.NPJ science of food · 2026Article
- Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.Journal of advanced research · 2026Article
- Impact of intra-tumoral microbiome on the efficacy of neoadjuvant immunochemotherapy in patients with locally advanced oral squamous cell carcinoma.Journal of translational medicine · 2026Article
- Review
- Exploring the role of metabolic disorders and gut microbiome in immune checkpoint regulation in cancer: PI3K/AKT/mTOR focus.Journal of physiology and biochemistry · 2026Review
- Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discover oncology · 2026Review
- The interplay between bile acid metabolism and gut microbiome in biliary tract cancers.Frontiers in microbiomes · 2026Review
- Prognostic Role of Gut Microbiota and Clinical Parameters in Predicting Survival in Advanced Cholangiocarcinoma Patients Receiving Chemotherapy.International journal of medical sciences · 2026Article
- The role of theFrontiers in microbiology · 2026Review
- Understanding the human gut microbiome: from composition to disease association.Frontiers in microbiomes · 2026Review
- Harnessing the microbiome: unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies.Clinical and molecular hepatology · 2026Review
- Immunotherapy in advanced biliary tract cancer: current status and future directions.Frontiers in pharmacology · 2026Review
- Seasonal dietary shifts drive gut microbiome plasticity and metabolic adaptation in wild yaks on the Qinghai-Xizang Plateau.BMC microbiology · 2025Article
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.NPJ biofilms and microbiomes · 2025Article
- Qingjie Fuzheng Granule prevents colitis-associated colorectal cancer by inhibiting abnormal activation of NOD2/NF-Chinese herbal medicines · 2025Article
- Review
- Associations of the gut microbiome and metabolites on biliary tract cancer: insight from a bidirectional two-sample Mendelian randomization study.Hepatobiliary surgery and nutrition · 2025Article
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Funding
Abstract
backgroundAccumulating evidence suggests that the gut microbiota and metabolites can modulate tumor responses to immunotherapy; however, limited data has been reported on biliary tract cancer (BTC). This study used metagenomics and metabolomics to identify characteristics of the gut microbiome and metabolites in immunotherapy-treated BTC and their potential as prognostic and predictive biomarkers.
methodsThis prospective cohort study enrolled 88 patients with BTC who received PD-1/PD-L1 inhibitors from November 2018 to May 2022. The microbiota and metabolites significantly enriched in different immunotherapy response groups were identified through metagenomics and LC-MS/MS. Associations between microbiota and metabolites, microbiota and clinical factors, and metabolites and clinical factors were explored.
resultsSignificantly different bacteria and their metabolites were both identified in the durable clinical benefit (DCB) and non-durable clinical benefit (NDB) groups. Of these, 20 bacteria and two metabolites were significantly associated with survival. Alistipes were positively correlated with survival, while Bacilli, Lactobacillales, and Pyrrolidine were negatively correlated with survival. Predictive models based on six bacteria, four metabolites, and the combination of three bacteria and two metabolites could all discriminated between patients in the DCB and NDB groups with high accuracy. Beta diversity between two groups was significantly different, and the composition varied with differences in the use of immunotherapy.
conclusionsPatients with BTC receiving immunotherapy have specific alterations in the interactions between microbiota and metabolites. These findings suggest that gut microbiota and metabolites are potential prognostic and predictive biomarkers for clinical outcomes of anti-PD-1/PD-L1-treated BTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.